Vaxcyte Inc (NAS:PCVX)
$ 102.7 -1.37 (-1.32%) Market Cap: 12.80 Bil Enterprise Value: 10.82 Bil PE Ratio: 0 PB Ratio: 3.79 GF Score: 40/100

Vaxcyte Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 13, 2021 / 07:30PM GMT
Release Date Price: $19.09 (+2.25%)
Chi Meng Fong
BofA Securities, Research Division - VP & Research Analyst

Good afternoon, everyone. Thanks for joining the BofA Annual Healthcare Conference. My name is Chi Fong. I'm one of the associates who work on Jason Gerberry's biopharmacy here at Bank of America. I'm pleased to introduce Grant Pickering, co-Founder and CEO of Vaxcyte. Vaxcyte's a development stage biopharma company developing next-generation vaccines, and Grant will kick things off with the company's presentation. After that, he will be joined by some of his colleagues in our Q&A. So now I'll turn the floor to Grant so to speak for the opening presentation.

Grant E. Pickering
Vaxcyte, Inc. - Co-Founder, CEO & Director

Yes. Thanks, Chi. I'd like to thank the BofA team for inviting us. We appreciate this opportunity to tell the Vaxcyte story. Can I get the slides brought up so they can appear on the screen? Or do I pull those up myself? That's okay. All right. Just give me a sec to pull them up. I have them pretty much memorized but not entirely.

So first things

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot